Comparative Pharmacology
Head-to-head clinical analysis: CHLORHEXIDINE GLUCONATE versus ORAQIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORHEXIDINE GLUCONATE versus ORAQIX.
CHLORHEXIDINE GLUCONATE vs ORAQIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cationic bisbiguanide that disrupts microbial cell membranes by binding to negatively charged cell wall components, increasing permeability and causing leakage of cytoplasmic contents; also inhibits bacterial enzymes and precipitates cytoplasmic constituents.
Oraqix is a eutectic mixture of lidocaine and prilocaine that acts as a local anesthetic. It reversibly blocks sodium ion channels in nerve cell membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing anesthesia.
Oral rinse: 15 mL of 0.12% solution swished in mouth for 30 seconds twice daily; topical: apply 2% cream or lotion to affected area 2-3 times daily.
750 mg orally once daily for 5 days; or 250 mg orally once daily for 5 days (levofloxacin equivalent).
None Documented
None Documented
Terminal half-life approximately 12-24 hours; may be prolonged in hepatic impairment.
Terminal elimination half-life: 7.5 hours (range 6-9 h) in patients with normal renal function; extends to 20-30 h in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Primarily renal (10-30% unchanged) and biliary/fecal (majority as metabolites).
Renal: ~60% unchanged; biliary/fecal: ~30% as metabolites and parent drug; total clearance approximates renal clearance.
Category C
Category C
Antiseptic
Antiseptic